Temporary renal insufficiency associated with topical tacrolimus treatment of multilocal pyoderma gangrenosum

Journal of Dermatological Case Reports

Volumn 7, Issue 3, 2013, Pages 106-107

  Wollina, Uwe ^a  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIPYRONE; HYDROMORPHONE; METHYLPREDNISOLONE; MORPHINE; MORPHINE SULFATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANTOPRAZOLE; TACROLIMUS;

ADULT; BACKACHE; CASE REPORT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LETTER; MALE; PYODERMA GANGRENOSUM;

EID: 84886899386     PISSN: None     EISSN: 18987249     Source Type: Journal    
DOI: 10.3315/jdcr.2013.1154     Document Type: Letter

References (7)

1. Nainani N, Patel N, Tahir N, Kumar R, Weber-Shrikant E, Gundroo AA, Murray BM, Tornatore KM, Blessios GA, Ve-nuto RC. Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function. Nephrol Dial Transplant. 2012; 27: 2077-2083. PMID: 22058172.
2. Pallet N, Legendre C. Deciphering calcineurin inhibitor neph-rotoxicity: a pharmacological approach. Pharmacogenomics. 2010; 11: 1491-1501. PMID: 21047207.
3. Metalidis C, Lerut E, Naesens M, Kuypers DR. Expression of CYP3A5 and P-glycoprotein in renal allografts with histologi-cal signs of calcineurin inhibitor nephrotoxicity. Transplantation. 2011; 91: 1098-1102. PMID: 21544031.
4. Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues. J Dtsch Dermatol Ges. 2012; 10: 167-172. PMID: 21974750.
5. Chandrasekhara PK, Jayachandran NV, Thomas J, Agrawal S, Narsimulu G. Successful treatment of pyoderma gangreno-sum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone. Clin Rheumatol. 2009; 28: 489-490. PMID: 19189166.
6. Güttler K, Sabatowski R. Differential therapeutic aspects of analgesia with oral sustained-release strong opioids. Application intervals, metabolism and immunosuppression. Schmerz. 2008; 22: 562-570. PMID: 18483817.
7. Picard N, Cresteil T, Prémaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004; 26: 600-608. PMID: 15570183.